Written questions by Anderson.

What assessment his department has made of the potential merits of a national rollout of community diagnostic centres to improve access to primary care services for people with pancreatic cancer.

The Department remains committed to improving access to cancer diagnostic services and treatment, including for harder to diagnose tumour types such as pancreatic cancer.The Government’s continued investment in community diagnostic centres (CDCs) enables the National Health Service to now deliver additional checks, tests, and scans at 170 CDCs, all of which deliver services 12 hours a day, seven days a week. This will enable the NHS to diagnose cancer faster and ensure that cancer patients, including those with pancreatic cancer, have timely access to primary care services.

What steps his department is taking to expand the roll out surveillance programmes to (a) identify people at highest risk of pancreatic cancer and (b) support earlier diagnosis.

Earlier diagnosis of cancers, including pancreatic cancer, is a priority for the Government. NHS England is working on case-finding approaches for less survivable cancers, where the evidence suggests this is appropriate. This includes a public-facing Family History Checker, which enables people, and their families, affected by pancreatic cancer to self-assess if they may inherit risk. Individuals identified as being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trial, which aims to understand inherited conditions of the pancreas. Referrals to the trial can be made by any healthcare professional across all health sectors or by individuals via self-referral, contributing to a centralised approach to case-finding.The National Disease Registration Service has developed the National Inherited Cancer Predisposition Register (NICPR), which launched on 30 June. The NICPR looks at a wide range of cancers for which there is an increased inherited risk, including for less survivable cancers. It aims to identify high-risk individuals who are eligible for targeted screening and surveillance and will act as an electronic referral route into national screening programmes, where these exist.

What information his Department holds on the availability of Sleepio as a treatment for insomnia in different Integrated Care Board areas; and whether he plans to increase access to Sleepio in (a) South West London ICB and (b) others across the UK where it is not available.

The Department does not hold information relating to the availability of Sleepio at integrated care board (ICB) level or information on the plans to increase access to Sleepio in the NHS South West London ICB. The decision to commission Sleepio and other digital health technologies is currently determined at local level, by National Health Service organisations.The Department is committed to exploring options to make digital tools, supporting people living with insomnia, nationally available. As set out in the 10-Year Health Plan, the Department has committed to piloting a HealthStore app marketplace. The store will explore options to support the availability of digital health technologies across multiple condition areas.NHS England are currently running an open process to secure equitable national access to digital Cognitive Behavioural Therapies for Insomnia and has recently published a Request For Information and questionnaire. This creates an opportunity for all suppliers in this market to engage in a fair and transparent commercial process.